Clinical considerations on the relationship between epilepsy and cardiovascular diseases
More details
Hide details
Chair and Department of Internal Medicine, Medical University, Lublin, Poland
Chair and Department of Obstetrics and Perinatology, Medical University, Lublin, Poland
Chair and Department of Cardiology, Medical University, Lublin, Poland
Department of Pathophysiology, Medical University, Lublin, Poland; Department of Physiopathology, Institute of Agricultural Medicine, Lublin, Poland
Corresponding author
Stanisław Czuczwar   

Department of Pathophysiology, Medical University, Lublin, Jaczewskiego 8, 20-090 Lublin, Poland
J Pre Clin Clin Res. 2007;1(1):6-8
There have been reports regarding higher risk of unexpected death in epileptic patients. The aim of this review is to investigate causes of epilepsy-related death with special attention to cardiovascular mechanisms. Due to their high incidence among the general population, epilepsy and cardiovascular diseases are likely to coexist in a certain proportion of patients. The effect of calcium channel antagonists – representing drugs commonly used in cardiac pathology – on seizure control is also discussed on the basis of available experimental data.
Sander JWAS, Shovron SD: The epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996, 61, 433-443.
Zdrojewski T, Wyrzykowski B, Szczech R, Wierucki L, Naruszewicz M, Narkiewicz K, Zarzeczna-Baran M, Steering Committees of the Programmes NATPOL PLUS, SMS, The Polish 400-Cities Project: Epidemiology and prevention of arterial hypertension in Poland. Blood Press Suppl 2005, 2, 10-16.
Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349, 1436- 1442.
Ficker DM, So EL, Shen WK, Annegers JF, O´Brien C, Cascino PGD, Belau PG: Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998, 51, 1270-1274.
Basile J: The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004, 6, 621-629.
Opie LH: Calcium channel blockers in hypertension: reappraisal after new trials and major meta-analyses. Am J Hypertens 2001, 14, 1074- 1081.
Grossman E, Messerli FH: Calcium antagonists. Prog Cardiovasc Dis 2004, 47, 34-57.
Romero M, Sanchez I, Pujol MD: New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships. Curr Med Chem Cardiovasc Hematol Agents 2003, 1, 113-141.
Katz AM.: Calcium channel diversity in the cardiovascular system. JACC 1996, 28, 522-529.
Fox AP, Nowycky MC, Tsien RW: Kinetic and pharmacological properties distinguishing three types of calcium currents in chick sensory neurones. J Physiol 1987, 394, 149-172.
Overweg J, Binnie CD, Meijer JW, Meinardi H, Nuijten ST, Schmaltz S, Wauquier A: Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1984, 25, 217-222.
Binnie CD: Flunarizine in epilepsy. Ann of NY Acad Sci 1988, 522, 710-711.
Overweg J, Binnie CD: Clinical treatment of epilepsy with calcium entry blockers. Funct Neurol 1986, 1, 539-541.
Southam E, Stratton SC, Davies CH: Anticonvulsant mechanisms for today and tomorrow. Drug News Perspect 2005, 18, 483-487.
Borowicz KK, Gąsior M, Kleinrok Z, Czuczwar SJ: Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. Eur J Pharmacol 1997, 323, 45- 51.
Czuczwar SJ, Chodkowska A, Kleinrok Z, Małek U, Jagiełło-Wójtowicz E: Effects of calcium channel inhibitors upon the efficacy of common antiepileptic drugs. Eur J Pharmacol 1990, 176, 75-83.
Czuczwar SJ, Gąsior M, Janusz W, Kleinrok Z: Influence of flunarizine, nicardipine and nimodipine on the anticonvulsant activity of different antiepileptic drugs in mice. Neuropharmacology 1992, 31, 1179-1183.
Kamiński R, Jasiński M, Jagiełło-Wójtowicz E, Kleinrok Z, Czuczwar SJ: Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Res 1999, 40, 319-325.
Borowicz KK, Kleinrok Z, Czuczwar SJ: Niguldipine impairs the protective activity of carbamazepine and phenobarbital in amygdalakindled seizures in rats. Eur Neuropsychopharmacol 2002, 12, 225- 233.
Benavente-Aguilar I, Morales-Blanquez C, Rubio EA, Rey JM: Quality of life of adolescents suffering from epilepsy living in the community. J Paediat Child Health 2004, 40, 110-113.
McEwan MJ, Espie CA, Metcalfe J, Brodie MJ, Wilson MT: Quality of life and psychosocial development in adolescents with epilepsy: a qualitative investigation using focus group methods. Seizure 2004, 13, 15-31.
Nakane Y, Seino M, Yaqi K, Kaji S, Yamauchi T: Effects of flunarizine on intractable epilepsy. Arzneimittelforschung 1989, 39, 793-798.
Czuczwar SJ: Doświadczalne podstawy racjonalnej politerapii. Epileptologia 1998, 6, 231-247.
Annegers JF, Coan PS: SUDEP: overview of definitions and review of incidence data. Seizure 1999, 8, 347-352.
Racoosin JA, Feeney J, Burkhart G, Boehm G: Mortality in antiepileptic drug development programs. Neurology 2001, 56, 514-519.
Bell GS, Sander JW: Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: a reappraisal. Acta Neurol Taiwan 2006, 15, 72-83.
Freeman R: Cardiovascular manifestations of autonomic epilepsy. Clin Auton Res 2006, 16, 12-17.
Lathers CM, Schraeder PL: Clinical pharmacology: drugs as a benefitand/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 2002, 42, 123-136.
Tigaran S, Molgaard H, McClelland R, Dam M, Jaffe AS: Evidence of cardiac ischemia during seizures in drug refractory epilepsy patients Neurology 2003, 60, 492-495.
Walczak T: Do antiepileptic drugs play a role in sudden unexpected death in eplilepsy? Drug Safety 2003, 26, 673-683.
Zijlmans M, Flanagan D, Gotman J: Heart rate changes and ECG abnormalities during epileptic seizures: prevalence and definition of an objective clinical sign. Epilepsia 2002, 43, 847-854.
Lathers CM, Schraeder PL, Weiner FL: Synchronization of cardiac autonomic neural discharge with epileptogenic activity: the lockstep phenomenon. Electroencephalogr Clin Neurophysiol 1987, 67, 247- 259.
Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S: Hyponatremia massociated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994, 35, 181-188.
Schmidt D, Sachdeo R: Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 2000, 1, 396-405.
Rocamora R, Kurthen M, Lickfett L, von Oertzen J, Elger CE: Cardiac asystole in epilepsy: clinical and neurophysiologic features. Epilepsia 2003, 44, 179-185.
Stőllberger C, Finsterer J: Cardiorespiratory findings in sudden unexplained/unexpected death in epilepsy (SUDEP). Epilepsy Res 2004, 59, 51-60.
Devinsky O, Pacia S, Tatambhotla G: Bradycardia and asystole induced by partial seizures: a case report and literature review. Neurology 1997, 6, 1712-1714.
Nilsson L, Diwan V, Farahmand BY, Persson PG, Tomson T: Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case-control study. Epilepsia 2001, 42, 667-673.
Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder P, Siscovick D, Wannamaker BB, Tennis PS, Cierpial MA, Earl NL: Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 1997, 38, 47-55.
Ng SKC, Hauser WA, Burst JCM, Susser M: Hypertension and risk of new-onset unprovoked seizures. Neurology 1993, 43, 425-428.
Journals System - logo
Scroll to top